Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATP12A
REST API REST API
Homo sapiens
ATP12A is differentially expressed in 158 experiments: 85 organism parts: trachea, kidney, ... (83 more);, 92 disease states: normal, gastric carcinoma, ... (90 more);, 47 cell types 101 cell lines 19 compound treatments and 56 other conditions.
Synonyms ATP1AL1
Orthologs F1NZB7_CHICK (Gallus gallus)   F1N1K4_BOVIN (Bos taurus)   Atp12a (Rattus norvegicus)   Atp12a (Mus musculus)   F6SG42_CIOIN (Ciona intestinalis)   Atpalpha (Drosophila melanogaster)   NP_001005025.1 (Xenopus laevis)   O77803_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term hydrogen:potassium-exchanging ATPase activity, plasma membrane, ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism, metal ion transport, membrane, metabolic process, metal ion binding, cation transport, potassium ion transport, monovalent inorganic cation transport, monovalent inorganic cation transmembrane transporter activity, ATP binding, proton transport, hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances, nucleotide binding, response to metal ion, ATP biosynthetic process, apical plasma membrane, integral to membrane, hydrolase activity, transmembrane transport, catalytic activity, potassium ion homeostasis, hydrogen:potassium-exchanging ATPase complex, ion transmembrane transport, response to organic cyclic compound
InterPro Term Dehalogen-like_hydro, ATPase_P-typ_cation-exchng_asu, ATPase_P-typ_cation-transptr_N, ATPase_P-typ_cation-transptr_C, ATPase_P-typ_cation-ex_asu_euk, ATPase_P-typ_ion-transptr, ATPase_P-typ_ATPase-assoc-dom
UniProt Accession P54707
Search EB-eye ENSG00000075673
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-7224, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-19639, E-GEOD-29119, E-GEOD-18005, ... (14 experiments)

Factor Value U/D Experiments
SW480
2
E-MEXP-1014, E-GEOD-18005
C3A
1
E-MTAB-37
BV173
1
E-MTAB-37
TERV-AntiSenseB56
1
E-MTAB-62
EM2
1
E-MTAB-37
293t-tva
1
E-MTAB-62
95 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (25 experiments)

Factor Value U/D Experiments
721 B lymphoblast
1
1
E-AFMX-5
chondrocyte
1
E-TABM-130
PBMCs
1
E-GEOD-20677
naive T cell
1
E-GEOD-1460
testis - leydig cell
1
E-AFMX-5
Monocytes
1
E-GEOD-21909
41 more value(s).


Disease state

studied in E-GEOD-5390, E-GEOD-3307, E-GEOD-19743, E-GEOD-15960, E-GEOD-2685, ... (23 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
E-MTAB-37
Calpain 3 mutation
1
E-GEOD-3307
squamous cell carcinoma cell line, control sample without infection after 8h
1
E-MTAB-62
septic shock
1
E-GEOD-9692
experimental malaria-infected
1
E-GEOD-5418
dermatomyositis
1
E-GEOD-5370
86 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-7216, E-GEOD-5824, ... (9 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-GEOD-7307, E-GEOD-995
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
hydrogen peroxide
1
E-GEOD-5339
Cxcl12
1
E-GEOD-7307
no estradiol
1
E-GEOD-20081
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
13 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
29
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-994, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-1561, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-361

Genotype
studied in E-GEOD-22056, E-GEOD-17476, E-TABM-321, E-MTAB-114

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, E-GEOD-9764 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-GEOD-19519, E-GEOD-6919, ... (18 experiments)

Infection
studied in E-GEOD-980, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-22309

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

Race
studied in E-GEOD-5851

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-23984, E-GEOD-11428

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.488 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM